Correlia Biosystems

Correlia Biosystems is a private, early-revenue stage company commercializing the PIXI platform, an automated immunoassay system that accelerates protein biomarker analysis. Its core innovation is a proprietary microfluidic gel technology that uses electrophoresis to drive molecular interactions, drastically reducing assay time from hours to minutes while using ultra-low sample volumes. The company targets the proteomics and diagnostics markets, offering validated kits for common targets and customizable solutions, with initial validation and development support from major pharmaceutical partners.

The PIXI platform is a benchtop automated immunoassay system that uses a proprietary microfluidic gel and electrophoresis to accelerate protein binding. It replaces slow diffusive steps with electrically-driven analyte transport through a nanoporous capture substrate, enabling rapid, sensitive, and low-volume protein quantification.

Correlia competes in the automated immunoassay space against established players like Meso Scale Discovery (electrochemiluminescence) and Quanterix (single-molecule array technology). Its differentiation lies in its unique electrophoretic transport mechanism, which emphasizes speed (60-minute assays) and minimal sample consumption (1 µL), rather than solely on ultra-high sensitivity.